Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SNRS- Sunrise Technologies -- Ignore unavailable to you. Want to Upgrade?

To: Peter van Steennis who wrote (2841)	7/25/1999 12:05:00 AM
From: Jacques Chitte	Read Replies (1) \| Respond to of 4140

>I am sure the panel felt "at risk" if they approved the procedure with this knowledge. Imagine what an attorney would do to all of them if his clients eye sight was lost or further impaired.< That is sensible on the face of it, but there are some things that don't line up. 1) Visx would be liable in the same way as Snrs. Visx clearly doesn't always work. And Snrs has an extraordinary safety record. 2) The ODP panel was an unrelieved ambush. Snrs went in with the de facto reassurance that its application was in order. These things aren't like taking the SAT. there is dialog between the applicant and the agency. Big money of some sort came in and rigged the game.

To: Peter van Steennis who wrote (2841)	7/25/1999 12:37:00 AM
From: HerbVic	Read Replies (1) \| Respond to of 4140

>>On another matter, since over 11 millions shares traded Friday, who was doing all the buying? Even >>shorts had to theoretically buy and then sell to cover their short position. So who ended up with all the >>stock? Shorts have to buy to cover. They have already sold. That is why they are short. But they don't end up with the stock. It was borrowed when they sold it, so when they buy it they simply unborrow, or return it. The longs end up with the stock. Some hold through. Others were buying on the way down in anticipation of a reversal. As short covering kicks in Monday, there may be something of a dead cat bounce. It's a sad story. A company plays a little fast and loose with the ethics of medical discovery, only to find that the discovery could make the grade on it own merit, but in the end the company looses the most important battle over the unstated issue of character. No laws broken. No wrists slapped. Research performed, written, prepared and submitted for refusal. Questionable research, due only to a conflict of interest, leaving more questions as a company goes down. Sadder still is that those who might have been helped by the medical discovery may never get the chance to undergo the procedure. The question then, as always, remains, "What is the value of the company?" Is there intellectual property left over that would make SNRS a takeover candidate? Is there a buyout in the cards before this procedure can go forward? What advantage would the buyer be getting from SNRS over simply starting from scratch? What company would want to buy SNRS? What company would want to merge? VISX? BEAM? BEAM just acquired Autonomus and has pinned its star on the LADARVision® System. A wholly different and equally expensive laser for a single type procedure is not very synergistic with the marketing plans of VISX (or is it?), let alone such a small company as BEAM. Could a single white knight bail out the developers? Where is Bill Gates when a company needs him? I find it hard to believe that this is the end of the story... [dramatic pause] ... Stay tuned. HerbVic